NCT04779216View on ClinicalTrials.gov

Effects of Romosozumab on Bone Density in Women with Anorexia Nervosa

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

October 24, 2024

Study Completion Date

October 31, 2025

Conditions
Bone Density, LowBone LossAnorexia NervosaEating Disorders
Interventions
DRUG

Romosozumab Prefilled Syringe

Romosozumab 210mg Injection monthly for 12 months

DRUG

Placebo

Placebo Injection monthly for 12 months

DRUG

Alendronate 70Mg Tab

Alendronate 70mg PO weekly starting at 12 months through 24 months.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Karen Klahr Miller, MD

OTHER

NCT04779216 - Effects of Romosozumab on Bone Density in Women with Anorexia Nervosa | Biotech Hunter | Biotech Hunter